Citations

Clear

6273 citation(s) found for "To, Andrew".

Assessment of Left‐Sided Hemodynamics With Exercise in Patients With Continuous Flow Left Ventricular Assist Device Support
Inglis, Sara S. , Schettle, Sarah , Villavicencio, Mauricio A. , Spencer, Philip J. , Stulak, John M., Kushwaha, Sudhir S. , Behfar, Atta, Rosenbaum, Andrew , Schettle, Sarah D , Rosenbaum, Andrew N , Inglis, Sara S , Tang, Paul C. , Behfar, Atta

Mayo Clinic

Artificial Organs | March 13, 2025 | Volume: 49 | Issue: 9 | Pages: 1462-1469

10.1111/aor.14995 | PMID 40078038 Get It

ABSTRACT Background Addition of left heart catheterization (LHC) to exercise protocols allows for a unique focus on parameters of systolic and diastolic responses to increased activity in patients with left ventricular assist device (LVAD) support. Methods A retrospective review was conducted of all consecutive adult patients who underwent LHC with exercise for any indication from June 2017 to June 2023. For all patients, the relationship between exercise and parameters of LV systolic and diastolic response was assessed. Patients were divided into two cohorts based on the indication for testing: hemodynamic optimization (Optim, n = 5) or weaning consideration (Wean, n = 3). Results Eight patients (88% male, median age 57 years (IQR 44, 65)) were included. LVEF was 45% (IQR 45, 56) in Wean and 25% (IQR 20, 42) in Optim. LV systolic work index (LVSWI) increased more rapidly over levels of exercise in Wean vs. Optim (slope 46.3 vs. −0.625; p = 0.044) and LVSWI rose more quickly at lower levels of LV end diastolic pressure (LVEDP) in Wean vs. Optim (slope 219.5 vs. −2.008; p = 0.0026). Pulse power index was higher in Wean patients at baseline (0.046 (IQR 0.04, 0.07) vs. 0.016 (IQR 0.001, 0.04); p = 0.14) and peak exercise (0.12 (IQR 0.12, 0.12) vs. 0.06 (IQR 0.03, 0.1); p = 0.29). Conclusions Patients with favorable remodeling on LVAD support have significantly improved LV systolic and diastolic responses to exercise and a trend of higher systemic pulsatility. Improving our understanding of LV‐LVAD interactions with activity may aid in future efforts to improve exercise tolerance through speed modulation.
Novel Controlled Metabolic Accelerator for Obesity-Related HFpEF
Jorkasky, Diane K., Tarka, Elizabeth , Khan, Shaharyar M., Kitzman, Dalane W, Pandey, Ambarish , Lewis, Gregory D. , Borlaug, Barry A. , Shah, Sanjiv J , Sauer, Andrew J , Litwin, Sheldon E. , Sharma, Kavita, Kitzman, Dalane W.

Mayo Clinic

JAMA Cardiology | March 12, 2025 | Volume: 10 | Issue: 6 | Pages: 609

10.1001/jamacardio.2025.0103 | PMID 40072462 Get It

Importance Excess body fat plays a pivotal role in the pathogenesis of heart failure with preserved ejection fraction (HFpEF). HU6 is a novel, controlled metabolic accelerator that enhances mitochondrial uncoupling resulting in increased metabolism and fat-specific weight loss. Objective To assess efficacy and safety of HU6 in reducing body weight, improving peak volume of oxygen consumption (VO 2 ) and body composition among patients with obesity-related HFpEF. Design, Setting, and Participants The Exploratory Phase 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of HU6 for Subjects With Obese HFpEF (HuMAIN-HFpEF) trial was a multicenter, dose-escalation randomized clinical trial among patients with chronic stable HFpEF and obesity. Data were analyzed from July to October 2024. Intervention HU6 treatment for 19 weeks, starting at 150 mg per day and potentially up titrated to 450 mg per day based on safety and tolerability vs placebo. Main Outcomes and Measures The primary end point was change in body weight. Results Of 66 participants randomized (mean [SD] age, 64.5 [12] years; 38 female [58%]; mean [SD] weight, 110.9 [22.4] kg), 56 completed the trial. HU6 (vs placebo) significantly decreased weight (between-group difference, −2.86 kg; 95% CI, −4.68 to −1.04 kg; P = .003), total fat mass (between-group difference, −2.96 kg; 95% CI, −4.50 to −1.42 kg; P < .001), and percentage visceral fat (between-group difference,−1.3%; 95% CI, −2.1 to −0.5%; P = .003), with no significant loss of muscle mass. There were no statistically significant changes in peak VO 2 , 6-minute walk distance, Kansas City Cardiomyopathy Questionnaire score, high-sensitivity C-reactive protein level, N-terminal pro–brain natriuretic peptide level, or diastolic function. Serious adverse events were noted in 5 participants (4 in the HU6 group; 1 in the placebo group), including 1 death, all judged unrelated to treatment. Conclusions and Relevance Among patients with obesity-related HFpEF, treatment with HU6 for 19 weeks led to modest but statistically significant weight loss without significant changes in peak VO 2 . Larger trials of longer duration are warranted to determine whether longer-term administration of HU6 can improve exercise function, quality of life, and cardiovascular outcomes in this increasingly common disorder. Trial Registration ClinicalTrials.gov Identifier: NCT05284617
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025
Greenberg, P, Stone, Richard M. , Al‐Kali, Aref , Bennett, John M. , Borate, Uma , Brunner, Andrew M. , Chai‐Ho, Wanxing , Curtin, Peter , Gaensler, Karin, Gahvari, Zhubin, Garcia-Manero, Guillermo, Jacoby, Meagan A., Keel, Sioḃán , Khanal, Rashmi, Maness, Lori J., McMahon, Christine M. , Odenike, Olatoyosi , Osman, Afaf, Sallman, David A. , Sayar, Hamid , Shallis, Rory M. , Tanaka, Tiffany , Kovach, Emily, Nguyen, Jamie , Hochstetler, Cindy, Osman, Afaf E.G. , Osman, Afaf E G , Abaza, Yasmin , Anand, Sarah , Ball, Brian J. , Dezern, Amy Elizabeth , Garcia‐Manero, Guillermo , Griffiths, Elizabeth A. , Haque, Tamanna Zohra , Jonas, Brian A. , Kishtagari, Ashwin , Madanat, Yazan F. , McCurdy, Shannon , Reddy, Vishnu , Singh, Abhay , Thota, Swapna , Kovach, Emily

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 12, 2025 | Volume: 23 | Issue: 3 | Pages: 66-75

10.6004/jnccn.2025.0013 | PMID 40073835 Get It

The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and comprehensive care of patients with MDS based on a review of recent clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts is convened at least on an annual basis. During the annual meeting, the panel evaluates new and emerging data to inform their recommendations. These NCCN Guidelines Insights review the recent updates, including treatment recommendations both for lower-risk and higher-risk MDS, preference stratification of therapeutic agents, and emerging data on novel therapeutics.
Pediatric Central Nervous System Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Gajjar, Amar , Mahajan, Anita , Canan, Liz, Chi, Susan , Cluster, Andrew , Cole, Bonnie , Darlington, Wendy , Dorris, Kathleen , Elster, Jennifer , Franson, Andrea , Helgager, Jeffrey, Lin, Chi , Metrock, Laura, Nanda, Ronica H. , Partap, Sonia , Plant, Ashley , Reynolds, Renée M. , Stearns, Duncan , Storm, Phillip, Wang, Leo D. , Whipple, Nicholas , Zaky, Wafik , McMillian, Nicole R., Ramakrishnan, Swathi , Franson, Andrea , Bale, Tejus , Bowers, Daniel C. , Cohen, Kenneth J. , Coven, Scott L. , Ermoian, Ralph P. , George, Elizabeth , Landi, Daniel B. , Palmer, Joshua D. , Pruthi, Sumit , Wang, Anthony

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 12, 2025 | Volume: 23 | Issue: 3 | Pages: 113-130

10.6004/jnccn.2025.0012 | PMID 40073837 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Central Nervous System Cancers provide multidisciplinary diagnostic workup, staging, and treatment recommendations for diffuse high-grade gliomas and medulloblastomas in children and adolescents. This article summarizes the studies and panel discussion that serve as the rationale for comprehensive care recommendations included in the NCCN Guidelines for Pediatric Central Nervous System Cancers.
Anatomic Drivers of J-Sign Presence and Severity: If There Is a Jump, Look for a Bump
Dandu, Navya , Phillips, Andrew , Haneberg, Erik , Elias, Tristan J. , Wang, Zachary , Trasolini, Nicholas A. , Yanke, Adam B. , Yanke, Adam B , Haneberg, Erik C , Hevesi, Mario

Mayo Clinic

The American Journal of Sports Medicine | March 12, 2025 | Volume: 53 | Issue: 5 | Pages: 1119-1126

10.1177/03635465251322788 | PMID 40071349 Get It

Background: Medial patellofemoral ligament reconstruction is frequently indicated for recurrent lateral patellar instability. The preoperative presence and severity of a J-sign have been associated with poorer postoperative outcomes. Purpose: To determine the underlying anatomic factors that contribute to the presence, severity, and jumping quality of the J-sign. Study Design: Cross-sectional study; Level of evidence, 3. Methods: All patients undergoing evaluation for patellar instability at a single institution between 2013 and 2023 and healthy controls without patellar instability were included. Patients with a history of knee osteotomies were excluded. The presence of a jumping J-sign and its relationship to patellofemoral measures including the Caton-Deschamps Index (CDI), trochlear dysplasia (Dejour grade), tibial tubercle–trochlear groove (TT-TG) distance, tibial tubercle lateralization, trochlear bump height, mechanical alignment, femoral anteversion, tibial torsion, trochlear medialization, patellar width, axial patellar/trochlear overlap, patellar height, trochlear height, and knee rotation angle (KRA) were measured using standardized 1.5-T magnetic resonance imaging (MRI). Univariate pairwise and multivariable analyses were performed to determine the factors associated with J-sign presence, severity, and quality. Results: Of the 130 knees with patellar instability, 89 (68.5%) demonstrated a J-sign on physical examination. In total, 44 (33.8%) patients demonstrated a 1-quadrant J-sign, 32 (24.6%) demonstrated a 2-quadrant smooth J-sign, and 13 (10.0%) demonstrated a jumping J-sign. A total of 22 control, noninstability cases were included. On multivariable analysis, increasing TT-TG distance (OR, 1.1 increase per millimeter; P = .04), external KRA (OR, 1.1 increase per degree; P = .02), and increasing CDI (OR, 1.3 increase per 0.1 increase in CDI; P = .02) were associated with J-sign presence. Increasing bump height (OR, 1.72 increase per millimeter; P = .007) and decreasing patellar width (OR, 0.89 decrease per millimeter; P = .076) were associated with a larger J-sign, when present. Increasing bump height (OR, 1.80 increase per millimeter; P = .018), increasing patellar width (OR, 1.33 increase per millimeter; P = .047), and decreasing CDI (OR, 0.009 decrease per 0.01 increase in ratio; P = .008) were associated with a jumping J-sign in comparison with a smooth 2-quadrant J-sign. A KRA of 10° (AUC, 0.70) and a cartilaginous bump height of 6.6 mm (AUC, 0.73) were thresholds associated with jumping J-sign presence. Conclusion: The presence of a J-sign is associated with MRI findings of relatively greater external tibiofemoral rotation, increased TT-TG distance, and increased patellar height, while J-sign severity and jumping quality are associated with the presence of additional underlying trochlear factors such as increased bump height. The anatomic drivers identified in this study should be further evaluated as possible factors associated with suboptimal outcomes after surgical management.
Abstract A011: ATM inhibitors exploit checkpoint defects and ATM-dependent double strand break repair to induce mitotic cell death in TP53-mutant glioblastoma
Chen, Jiajia , Carlson, Brett L. , Calmo, Nery Matias , Tian, Shulan , Laverty, Daniel J. , Gupta, Shiv K. , Bradshaw, Gary Andrew , Sarkaria, Jann N. , Nagel, Zachary D

Mayo Clinic

Cancer Research | March 11, 2025 | Volume: 85 | Issue: 5_Supplement | Pages: A011-A011

10.1158/1538-7445.genfunc25-a011 Get It

Abstract Determining the balance between DNA double strand break repair (DSBR) pathways is essential for understanding treatment response in cancer. We report a method for simultaneously measuring non-homologous end joining (NHEJ), homologous recombination (HR), and microhomology-mediated end joining (MMEJ) and show that HR and MMEJ are therapeutically-targetable treatment resistance mechanisms in glioblastoma. Using a targeted screen of clinically relevant small molecules, we identify the ATM kinase inhibitor, AZD1390, as a potent dual HR/MMEJ inhibitor. Mechanistic studies in GBM cell lines show that AZD1390 suppresses DSB end resection and blocks radiation-induced phosphorylation of DSBR proteins including nibrin, Rad50, and Mettl16. Interestingly, AZD1390 enhances the cytotoxic effects of TMZ and radiation in both treatment-naïve and treatment-resistant GBM samples harboring mutations in the TP53 gene. We show that TP53 mutation is associated with upregulation of ATM pathway genes in GBM patient samples along with heightened ATM-dependent HR and MMEJ in GBM cell lines. Finally, we show that TP53-mutant GBMs fail to arrest in G2 phase after radiation/AZD1390 or TMZ/AZD1390 combinations and instead attempt mitosis, leading to mitotic cell death. Expression of the mitotic DSBR factor, RHINO1, is associated with poor prognosis in patients with TP53-mutant GBMs, suggesting that factors that promote efficient mitotic DSBR protect TP53-mutant GBMs from treatment-induced cell death. This report identifies ATM-dependent HR and MMEJ as targetable resistance mechanisms in TP53-mutant GBM and establishes ATM inhibition as a potential strategy for overcoming intrinsic and acquired treatment resistance in TP53-mutant GBMs. Citation Format: Daniel J Laverty, Shiv Gupta, Gary Bradshaw, Jiajia Chen, Brett L Carlson, Nery Matias Calmo, Shulan Tian, Jann N Sarkaria, Zachary D Nagel. ATM inhibitors exploit checkpoint defects and ATM-dependent double strand break repair to induce mitotic cell death in TP53-mutant glioblastoma [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Functional and Genomic Precision Medicine in Cancer: Different Perspectives, Common Goals; 2025 Mar 11-13; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2025;85(5 Suppl):Abstract nr A011.
Evaluation of Innate Immune System, Body Habitus, and Sex on the Pharmacokinetics and Pharmacodynamics of Anetumab Ravtansine in Patients With Cancer
Chen, Li , Mansfield, Aaron S. , Lheureux, Stéphanie , O’Connor, C.J., Zamboni, Beth A., Patel, Kashish, McKee, Tawnya C., Moscow, Jeffrey A. , Zamboni, William C. , Mansfield, Aaron S , Lheureux, Stephanie , Moscow, Jeffrey A , Lucas, Andrew T.

Mayo Clinic

Clinical and Translational Science | March 11, 2025 | Volume: 18 | Issue: 3 | Pages: No page available

10.1111/cts.70178 | PMID 40051118 Get It

ABSTRACTAnetumab ravtansine, like other ADC drugs, has high inter‐patient variability in its pharmacokinetic (PK) and pharmacodynamic (PD) outcomes, which raises concerns about whether current dosing regimens are optimal for patients. The objective of this study was to evaluate covariates, especially body habitus and the innate immune system (IIS), which may affect anetumab ravtansine PK and PD as part of two clinical trials in patients with ovarian cancer and mesothelioma. Biomarkers of Fcγ receptors(FcγR) CD64 on IIS cells, total body weight (TBW), body surface area (BSA), and other covariates, such as sex and age, were analyzed for an association with anetumab ravtansine PK. Higher FcγR CD64, TBW, and BSA were associated with higher clearance (CL) of anetumab ravtansine (p < 0.05). However, there was no relationship between TBW or BSA and FcγR CD64. Female patients had a lower anetumab ravtansine CL (0.030 ± 0.007 L/h) compared to male patients (0.042 ± 0.006 L/h) (p < 0.05). In both studies, patients with stable disease (SD) and partial response (PR) had higher anetumab ravtansine AUC0‐inf compared to patients with progressive disease (PD). Individualizing the dose of anetumab ravtansine and potentially other ADCs based only on TBW is not optimal, whereas precision dosing of an ADC based on the inclusion of novel metrics of IIS biomarkers, body habitus, and sex may be more appropriate to reduce variability in PK exposure, reduce toxicity, and improve response.
Potential impact of hormone replacement therapy on the risk of hepatocellular carcinoma in women of the PLCO cohort
McCarthy, Nina S. , Redfern, Andrew , Orchard, Suzanne G. , Nguyen, Justin H. , Li, Zhaoyu , Li, Zhaoyu , Hickey, Martha

Mayo Clinic

Oncologie | March 10, 2025 | Volume: 27 | Issue: 2 | Pages: 307-313

10.1515/oncologie-2024-0547 Get It

Abstract Objectives Studies on the impact of hormone replacement therapy (HRT) on hepatocellular carcinoma (HCC) have been investigated in the past. This study aims to further address this topic using a large population dataset of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial (NIH, USA). Methods Multivariable logistic regression was used for the analysis of women in the entire PLCO cohort. Results A non-significant reduction in the risk of developing HCC was observed in women using HRT compared to never users (OR=0.61, 95 % CI: 0.21–1.79, p=0.367). Oral contraceptive use was significantly associated with reduced risk of HCC in the HRT group, (OR=0.17, 95 % CI: 0.00–0.82, p=0.028), and there was a nearly-significant interaction between HRT use and oral contraceptive use (p=0.054). Regardless of HRT use, those with pre-existing liver comorbidities of hepatitis or cirrhosis were at the highest risk of developing HCC (OR=5.09, 95 % CI: 1.13–22.81, p=0.034). However, liver comorbidities of hepatitis or cirrhosis and exposure to HRT showed a significant interaction (p=0.0001). Conclusions In those taking HRT, oral contraceptive use was significantly protective against HCC, suggesting that a longer period of hormone use (oral contraceptive plus HRT) provides additional protection against HCC than HRT alone. Overall, the low numbers of HCC diagnoses, which reflect the wider healthy female population, limited our ability to establish statistical significance regarding the impact of HRT on HCC incidence, which requires further prospective studies of larger populations.
Proceedings of the 29th Annual Congress of the International Liver Transplantation Society
Patel, Madhukar S. , Tejedor, Marta , Barbas, Andrew S. , Kim, Joohyun , Shingina, Alexandra , Wilson, Elizabeth A. , Alconchel, Felipe , Patel, Dhupal , Liu, Jiang , Mazzola, Alessandra, Tanaka, Tomohiro , Victor, David W. , Yoon, Young-in, Vinaixa, Carmen , Kyaw, Aye Mya Mya , Galante, Antonio, Kathirvel, Manikandan , Moral, Kenan , Maira, Tommaso Di , Martin, Eléonora De , Mao, Shennen, Tejedor, Marta , Wilson, Elizabeth , Alconchel, Felipe , Di Maira, Tommaso , Shankar, Sadhana , Mao, Shennen A. , Ivanics, Tommy , Mathew, Johns Shaji , Khan, Mohammad Qasim , Syn, Nicholas L. X. , Nasralla, David , Mazzola, Alessandra , Yoon, Young-in, Magistri, Paolo , Aliseda, Daniel , Chadha, Ryan , Bonaccorsi‐Riani, Eliano , Rammohan, Ashwin , Patel, Madhukar

Mayo Clinic

Liver Transplantation | March 10, 2025 | Volume: 31 | Issue: 7 | Pages: 945-955

10.1097/lvt.0000000000000593 | PMID 40062745 Get It

The 2024 Annual Congress of the International Liver Transplantation Society (ILTS) was from May 1–4 in Houston, Texas, USA, under the theme “Liver Disease and Transplantation: Breaking Barriers and Exploring New Frontiers.” In addition to a robust scientific program, the congress also hosted a hands-on cadaveric robotic liver surgery course, a machine perfusion workshop, and a transesophageal echocardiography course. In this report, the ILTS Vanguard and Basic Sciences Committees present a summary of the congress proceedings.
Outcomes after en bloc resection with sacrectomy of advanced colorectal carcinomas that invade the sacrum: a multiinstitutional descriptive series
Pieters, Thomas A. , Elsamadicy, Aladine A. , Pennington, Zach , Najjar, Salem , Ber, Roee , Efron, Jonathan E., Gearhart, Susan L. , Safar, Bashar , Wolinsky, Jean-Paul, Sciubba, Daniel M. , Lo, Sheng-Fu Larry , Pennington, Zach , Hersh, Andrew M. , Santangelo, Gabrielle , Hung, Bethany , Atallah, Chady , Wolinsky, Jean‐Paul

Mayo Clinic

Journal of Neurosurgery: Spine | March 7, 2025 | Volume: 42 | Issue: 5 | Pages: 598-604

10.3171/2024.10.spine24391 | PMID 40053935 Get It

OBJECTIVE Management of locally invasive colorectal carcinoma at any stage currently involves surgical excision followed by chemoradiotherapy; however, the prognosis is poor, with a 5-year overall survival (OS) of only 5%. Failure to achieve gross-total resection is associated with poorer OS, and patients with residual tumor postresection (R1 or R2 resection) have a median OS of 7 months compared with 23 months in those who undergo resection with negative margins (R0 resection). For tumors that have invaded the sacrum, sacrectomy becomes necessary to achieve R0 resection. The objective of this study was to provide a descriptive multicenter account of resection for locally invasive colorectal carcinoma with sacral invasion, focusing on the association of tumor morphometry with surgical planning and perioperative outcomes. METHODS Demographic, comorbidity, clinical, tumor-specific, operative characteristic, and outcome data were collected on all patients who underwent resection of colorectal carcinoma with concurrent sacral resection between January 2005 and May 2022. Patients were grouped into those having undergone surgery for purely palliative intent, or those with resection with attempt at local control and dichotomized into level of osteotomy (either proximal or distal to the S2–3 level). RESULTS Twenty-two patients (median age 50.5 [IQR 43.3–60.0] years, 54.5% female) underwent sacrectomy for colorectal carcinoma. Operative records indicated intent for local control in 14 patients and palliative in the remaining 8 patients. Palliative surgical intent was based primarily on the presence of distant metastases. There was no significant difference in median local progression-free survival between patients undergoing osteotomy proximal to the S2–3 level and those undergoing osteotomy distal to the S2–3 level. CONCLUSIONS En bloc resection is believed to offer the best local control in patients with locally invasive colorectal carcinoma. The present descriptive series highlights outcomes of en bloc resection with partial or full sacrectomy in patients with tumors showing local extension into the sacrum. Complications are common, most often in the form of wound dehiscence or infection, and many patients require placement in a rehabilitation or intermediate-care facility upon discharge. However, for those with stage III (locally aggressive) disease, median OS exceeds 16 years, suggesting that such aggressive management with en bloc resection may be warranted in properly selected patients.